Close

FDA Approves Much Awaited Diabetic Drug Mounjaro From Lilly

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

$2 Billion Expansion By J&J in North Carolina Facility

Johnson & Johnson on August 21, 2025, went on...

Pharma Sector Reactions to US-EU Trade Framework Deal

The United States and the EU have, on August...

Chinese Pharmaceutical Firms Turn to Local Reagent Suppliers

The Chinese pharmaceutical firms are increasingly looking out for...

Trump Executive Order to Cover 26 Drugs Critical to Health

US president Donald Trump has gone on to direct...

 With high hopes, Eli Lilly’s Mounjaro (tirzepatide) was promoted to the big leagues in the week ending May 14, when the FDA approved the type 2 diabetes and weight-loss medication. Can Lilly score a home run with a medicine that has been demonstrated in clinical trials to be much more successful than other diabetes therapies in a highly competitive environment that Novo Nordisk leads? Mounjaro comes from a business that has battled Novo Nordisk for decades and is expected to produce $4.9 billion in revenue by 2026, according to an industry-specific portal. Last year, Mounjaro outperformed Novo’s blockbuster Ozempic in a head-to-head study, demonstrating that it was far more helpful in assisting individuals lose weight and regulate their blood sugar levels. In the United States, more than 30 million people have type 2 diabetes, with some struggling to achieve appropriate blood sugar levels despite the wide range of medications.

Mounjaro is a first-of-its-kind dual-action medication that stimulates both the GLP-1 and GIP receptors. The medication is given once a week, with the dose being tailored to the patient’s needs. In a phase 3 trial, individuals on the maximum 15 mg dosage of Mounjaro lost roughly 12 pounds more than on Ozempic, 29 pounds more than on insulin degludec, and 27 pounds higher than those on insulin glargine, with a BMI of 32–34.

Last year, Ozempic had sales of 33.7 billion Dutch krones, or approximately $5 billion. The medicine was approved by the FDA in 2017, and the higher-dose version was approved in March this year. Trulicity and Jardiance, Lilly’s current diabetes bestsellers, produced revenues of more than $10 billion last year. Lilly collaborates with Boehringer Ingelheim on Jardiance.

Lilly announced earlier this year that it may offer Mounjaro as a diabetes and obesity medication. Novo Nordisk, which offers Ozempic as Wegovy to obese patients, has seen success with this strategy.

Latest stories

Related stories

$2 Billion Expansion By J&J in North Carolina Facility

Johnson & Johnson on August 21, 2025, went on...

Pharma Sector Reactions to US-EU Trade Framework Deal

The United States and the EU have, on August...

Chinese Pharmaceutical Firms Turn to Local Reagent Suppliers

The Chinese pharmaceutical firms are increasingly looking out for...

Trump Executive Order to Cover 26 Drugs Critical to Health

US president Donald Trump has gone on to direct...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back